Imaginations of Feasibility, Method of Production and Benefits of Oral MMR Vaccine
DOI:
https://doi.org/10.62051/zns2m855Keywords:
MMR Vaccine; oral; benefit.Abstract
Measles, mumps and rubella are acute infectious diseases caused by viral infections in children and caused great harm before the use of vaccines. The Measles, Mumps and Rubella (MMR) oral vaccine indicates a breakthrough in the fight against three infectious diseases which are measles, mumps and rubella. Unlike the traditional injectable MMR vaccine. This oral vaccine does not require an injection, and it can improve patient acceptance. The purpose of this paper is to provide a comprehensive study of the development, efficacy and safety of the oral MMR vaccine and compare it with the traditional injectable vaccine. It will emphasize the benefits of oral vaccines, such as reduced needle-related fears and increased accessibility, which are particularly beneficial in resource-limited settings where needle vaccination may be impractical. In addition, this paper will discuss the challenges of maintaining vaccine stability, dosage accuracy, vaccine efficacy and safety. Through these analyses, this paper seeks to determine whether oral MMR vaccine can be a viable alternative to global immunization efforts.
Downloads
References
[1] The FDA approved M-M-R II in 1971 for use in people 12 months of age and older.
[2] Measles, Mumps, and Rubella (German Measles). 2020.https://www.fhs.gov.hk/english/health_info/child/486.html
[3] “Rubella – Fact Sheet for Parents,” cdc.gov.
[4] Wang H P, Wang Z G, Liu S L. Current status and future trends of vaccine development against viral infection and disease [J]. New Journal of Chemistry, 2021, 45 (17): 7437-7449.
[5] Stratton K, Ford A, Rusch E, Clayton EW, editors. Institute of Medicine. Adverse Effects of Vaccines: Evidence and Causality. Washington DC: National Academies Press; 2011. [PubMed] [Google Scholar]
[6] Naleway AL, Gold R, Drew L, Riedlinger K, Henninger ML, Gee J. Reported adverse events in young women following quadrivalent human papillomavirus vaccination. J Womens Health (Larchmt) 2012; 21 (4): 425–32.
[7] Woo EJ, Ball R, Braun MM. Fatal syncope-related fall after immunization. Arch Pediatr Adolesc Med. 2005; 159 (11): 1083.
[8] Braun MM, Patriarca PA, Ellenberg SS. Syncope after immunization. Arch Pediatr Adolesc Med. 1997; 151 (3): 255–9.
[9] Kroger AT, Sumaya CV, Pickering LK, Atkinson WL. General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices. MMWR. 2011; 60 (RR02): 1–60.
[10] “Editorial: Inactivated Measles Virus Vaccine,” British Medical Journal 1, no. 5294 (1962): 1746–1747. [PMC free article] [PubMed].
[11] Kowalzik F, Faber J, Knuf M. MMR and MMRV vaccines. Vaccine. 2018 Aug 28; 36 (36): 5402-5407.
Downloads
Published
Conference Proceedings Volume
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.